Front Pharmacol:研究揭示异柠檬酸内酯C在葡萄膜炎和视网膜炎性疾病中的治疗作用机制

2018-05-16 MedSci MedSci原创

本研究旨在探究天然成分异柠檬酸内酯C(LC53)对实验性内毒素诱导的葡萄膜炎(EIU)的眼部炎症及在小胶质细胞中的作用机制。评估前葡萄膜炎的严重程度表明LC53治疗明显降低了虹膜充血并恢复了临床评分。此外,视网膜电图检查的视网膜功能不足可通过LC53改善。在EIU期间LC53显著降低肿瘤坏死因子(TNF)-α、单核细胞趋化蛋白-1、蛋白质渗漏和基质金属蛋白酶的活性。此外,LC53治疗减少了后部GF

本研究旨在探究天然成分异柠檬酸内酯C(LC53)对实验性内毒素诱导的葡萄膜炎(EIU)的眼部炎症及在小胶质细胞中的作用机制。

评估前葡萄膜炎的严重程度表明LC53治疗明显降低了虹膜充血并恢复了临床评分。此外,视网膜电图检查的视网膜功能不足可通过LC53改善。在EIU期间LC53显著降低肿瘤坏死因子(TNF)-α、单核细胞趋化蛋白-1、蛋白质渗漏和基质金属蛋白酶的活性。此外,LC53治疗减少了后部GFAP和Iba-1的氧化应激以及神经炎症反应。LC53还降低了EIU中p65的磷酸化,HSP90、Bax和cleaved-caspase-3的表达。

对小胶质细胞的作用研究显示,LC53明显消除了LPS刺激的小胶质BV2细胞中TNF-α、PGE2、NO和ROS的产生,以及诱导型NO合酶和环加氧酶-2的表达。LC53可明显抑制IKKβ的小胶质细胞激活、p65磷酸化和核磷酸化的p65易位。另一方面,LC53表现出对JNK和ERK MAPK活化的抑制作用。

综上所述,该研究结果表明,LC53通过抑制EIU中的神经炎症、神经胶质激活和细胞凋亡来发挥眼保护作用,提示下调NF-κB信号通路在葡萄膜炎和视网膜炎性疾病中的治疗作用。

原始出处:


Fan-Li Lin, Jau-Der Ho, et al., Theissenolactone C Exhibited Ocular Protection of Endotoxin-Induced Uveitis by Attenuating Ocular Inflammatory Responses and Glial Activation. Front Pharmacol. 2018; 9: 326. doi:  10.3389/fphar.2018.00326

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1908422, encodeId=cac519084221c, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Jul 04 16:42:00 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745739, encodeId=a8b21e45739ba, content=<a href='/topic/show?id=93236698576' target=_blank style='color:#2F92EE;'>#炎性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66985, encryptionId=93236698576, topicName=炎性疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=629135549792, createdName=vividelife, createdTime=Sun Jan 27 15:42:00 CST 2019, time=2019-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787472, encodeId=9b571e87472e9, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sat Jul 14 23:42:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788307, encodeId=0da01e8830792, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sat Oct 06 22:42:00 CST 2018, time=2018-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996163, encodeId=769c1996163bf, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Wed Feb 27 19:42:00 CST 2019, time=2019-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1751396, encodeId=3ba21e5139676, content=<a href='/topic/show?id=138290e787c' target=_blank style='color:#2F92EE;'>#视网膜炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90778, encryptionId=138290e787c, topicName=视网膜炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sun Feb 24 11:42:00 CST 2019, time=2019-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270056, encodeId=2d0212e0056c3, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Fri May 18 04:42:00 CST 2018, time=2018-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542152, encodeId=ced7154215278, content=<a href='/topic/show?id=669d6185e3e' target=_blank style='color:#2F92EE;'>#柠檬酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61857, encryptionId=669d6185e3e, topicName=柠檬酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=725913361726, createdName=ms5236388012055669, createdTime=Fri May 18 04:42:00 CST 2018, time=2018-05-18, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1908422, encodeId=cac519084221c, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Jul 04 16:42:00 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745739, encodeId=a8b21e45739ba, content=<a href='/topic/show?id=93236698576' target=_blank style='color:#2F92EE;'>#炎性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66985, encryptionId=93236698576, topicName=炎性疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=629135549792, createdName=vividelife, createdTime=Sun Jan 27 15:42:00 CST 2019, time=2019-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787472, encodeId=9b571e87472e9, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sat Jul 14 23:42:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788307, encodeId=0da01e8830792, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sat Oct 06 22:42:00 CST 2018, time=2018-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996163, encodeId=769c1996163bf, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Wed Feb 27 19:42:00 CST 2019, time=2019-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1751396, encodeId=3ba21e5139676, content=<a href='/topic/show?id=138290e787c' target=_blank style='color:#2F92EE;'>#视网膜炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90778, encryptionId=138290e787c, topicName=视网膜炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sun Feb 24 11:42:00 CST 2019, time=2019-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270056, encodeId=2d0212e0056c3, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Fri May 18 04:42:00 CST 2018, time=2018-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542152, encodeId=ced7154215278, content=<a href='/topic/show?id=669d6185e3e' target=_blank style='color:#2F92EE;'>#柠檬酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61857, encryptionId=669d6185e3e, topicName=柠檬酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=725913361726, createdName=ms5236388012055669, createdTime=Fri May 18 04:42:00 CST 2018, time=2018-05-18, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1908422, encodeId=cac519084221c, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Jul 04 16:42:00 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745739, encodeId=a8b21e45739ba, content=<a href='/topic/show?id=93236698576' target=_blank style='color:#2F92EE;'>#炎性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66985, encryptionId=93236698576, topicName=炎性疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=629135549792, createdName=vividelife, createdTime=Sun Jan 27 15:42:00 CST 2019, time=2019-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787472, encodeId=9b571e87472e9, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sat Jul 14 23:42:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788307, encodeId=0da01e8830792, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sat Oct 06 22:42:00 CST 2018, time=2018-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996163, encodeId=769c1996163bf, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Wed Feb 27 19:42:00 CST 2019, time=2019-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1751396, encodeId=3ba21e5139676, content=<a href='/topic/show?id=138290e787c' target=_blank style='color:#2F92EE;'>#视网膜炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90778, encryptionId=138290e787c, topicName=视网膜炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sun Feb 24 11:42:00 CST 2019, time=2019-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270056, encodeId=2d0212e0056c3, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Fri May 18 04:42:00 CST 2018, time=2018-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542152, encodeId=ced7154215278, content=<a href='/topic/show?id=669d6185e3e' target=_blank style='color:#2F92EE;'>#柠檬酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61857, encryptionId=669d6185e3e, topicName=柠檬酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=725913361726, createdName=ms5236388012055669, createdTime=Fri May 18 04:42:00 CST 2018, time=2018-05-18, status=1, ipAttribution=)]
    2018-07-14 jj000001
  4. [GetPortalCommentsPageByObjectIdResponse(id=1908422, encodeId=cac519084221c, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Jul 04 16:42:00 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745739, encodeId=a8b21e45739ba, content=<a href='/topic/show?id=93236698576' target=_blank style='color:#2F92EE;'>#炎性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66985, encryptionId=93236698576, topicName=炎性疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=629135549792, createdName=vividelife, createdTime=Sun Jan 27 15:42:00 CST 2019, time=2019-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787472, encodeId=9b571e87472e9, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sat Jul 14 23:42:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788307, encodeId=0da01e8830792, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sat Oct 06 22:42:00 CST 2018, time=2018-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996163, encodeId=769c1996163bf, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Wed Feb 27 19:42:00 CST 2019, time=2019-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1751396, encodeId=3ba21e5139676, content=<a href='/topic/show?id=138290e787c' target=_blank style='color:#2F92EE;'>#视网膜炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90778, encryptionId=138290e787c, topicName=视网膜炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sun Feb 24 11:42:00 CST 2019, time=2019-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270056, encodeId=2d0212e0056c3, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Fri May 18 04:42:00 CST 2018, time=2018-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542152, encodeId=ced7154215278, content=<a href='/topic/show?id=669d6185e3e' target=_blank style='color:#2F92EE;'>#柠檬酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61857, encryptionId=669d6185e3e, topicName=柠檬酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=725913361726, createdName=ms5236388012055669, createdTime=Fri May 18 04:42:00 CST 2018, time=2018-05-18, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1908422, encodeId=cac519084221c, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Jul 04 16:42:00 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745739, encodeId=a8b21e45739ba, content=<a href='/topic/show?id=93236698576' target=_blank style='color:#2F92EE;'>#炎性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66985, encryptionId=93236698576, topicName=炎性疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=629135549792, createdName=vividelife, createdTime=Sun Jan 27 15:42:00 CST 2019, time=2019-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787472, encodeId=9b571e87472e9, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sat Jul 14 23:42:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788307, encodeId=0da01e8830792, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sat Oct 06 22:42:00 CST 2018, time=2018-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996163, encodeId=769c1996163bf, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Wed Feb 27 19:42:00 CST 2019, time=2019-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1751396, encodeId=3ba21e5139676, content=<a href='/topic/show?id=138290e787c' target=_blank style='color:#2F92EE;'>#视网膜炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90778, encryptionId=138290e787c, topicName=视网膜炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sun Feb 24 11:42:00 CST 2019, time=2019-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270056, encodeId=2d0212e0056c3, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Fri May 18 04:42:00 CST 2018, time=2018-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542152, encodeId=ced7154215278, content=<a href='/topic/show?id=669d6185e3e' target=_blank style='color:#2F92EE;'>#柠檬酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61857, encryptionId=669d6185e3e, topicName=柠檬酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=725913361726, createdName=ms5236388012055669, createdTime=Fri May 18 04:42:00 CST 2018, time=2018-05-18, status=1, ipAttribution=)]
    2019-02-27 yb6560
  6. [GetPortalCommentsPageByObjectIdResponse(id=1908422, encodeId=cac519084221c, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Jul 04 16:42:00 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745739, encodeId=a8b21e45739ba, content=<a href='/topic/show?id=93236698576' target=_blank style='color:#2F92EE;'>#炎性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66985, encryptionId=93236698576, topicName=炎性疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=629135549792, createdName=vividelife, createdTime=Sun Jan 27 15:42:00 CST 2019, time=2019-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787472, encodeId=9b571e87472e9, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sat Jul 14 23:42:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788307, encodeId=0da01e8830792, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sat Oct 06 22:42:00 CST 2018, time=2018-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996163, encodeId=769c1996163bf, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Wed Feb 27 19:42:00 CST 2019, time=2019-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1751396, encodeId=3ba21e5139676, content=<a href='/topic/show?id=138290e787c' target=_blank style='color:#2F92EE;'>#视网膜炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90778, encryptionId=138290e787c, topicName=视网膜炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sun Feb 24 11:42:00 CST 2019, time=2019-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270056, encodeId=2d0212e0056c3, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Fri May 18 04:42:00 CST 2018, time=2018-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542152, encodeId=ced7154215278, content=<a href='/topic/show?id=669d6185e3e' target=_blank style='color:#2F92EE;'>#柠檬酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61857, encryptionId=669d6185e3e, topicName=柠檬酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=725913361726, createdName=ms5236388012055669, createdTime=Fri May 18 04:42:00 CST 2018, time=2018-05-18, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1908422, encodeId=cac519084221c, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Jul 04 16:42:00 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745739, encodeId=a8b21e45739ba, content=<a href='/topic/show?id=93236698576' target=_blank style='color:#2F92EE;'>#炎性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66985, encryptionId=93236698576, topicName=炎性疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=629135549792, createdName=vividelife, createdTime=Sun Jan 27 15:42:00 CST 2019, time=2019-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787472, encodeId=9b571e87472e9, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sat Jul 14 23:42:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788307, encodeId=0da01e8830792, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sat Oct 06 22:42:00 CST 2018, time=2018-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996163, encodeId=769c1996163bf, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Wed Feb 27 19:42:00 CST 2019, time=2019-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1751396, encodeId=3ba21e5139676, content=<a href='/topic/show?id=138290e787c' target=_blank style='color:#2F92EE;'>#视网膜炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90778, encryptionId=138290e787c, topicName=视网膜炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sun Feb 24 11:42:00 CST 2019, time=2019-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270056, encodeId=2d0212e0056c3, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Fri May 18 04:42:00 CST 2018, time=2018-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542152, encodeId=ced7154215278, content=<a href='/topic/show?id=669d6185e3e' target=_blank style='color:#2F92EE;'>#柠檬酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61857, encryptionId=669d6185e3e, topicName=柠檬酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=725913361726, createdName=ms5236388012055669, createdTime=Fri May 18 04:42:00 CST 2018, time=2018-05-18, status=1, ipAttribution=)]
    2018-05-18 zutt
  8. [GetPortalCommentsPageByObjectIdResponse(id=1908422, encodeId=cac519084221c, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Jul 04 16:42:00 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745739, encodeId=a8b21e45739ba, content=<a href='/topic/show?id=93236698576' target=_blank style='color:#2F92EE;'>#炎性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66985, encryptionId=93236698576, topicName=炎性疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=629135549792, createdName=vividelife, createdTime=Sun Jan 27 15:42:00 CST 2019, time=2019-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787472, encodeId=9b571e87472e9, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sat Jul 14 23:42:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788307, encodeId=0da01e8830792, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sat Oct 06 22:42:00 CST 2018, time=2018-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996163, encodeId=769c1996163bf, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Wed Feb 27 19:42:00 CST 2019, time=2019-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1751396, encodeId=3ba21e5139676, content=<a href='/topic/show?id=138290e787c' target=_blank style='color:#2F92EE;'>#视网膜炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90778, encryptionId=138290e787c, topicName=视网膜炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sun Feb 24 11:42:00 CST 2019, time=2019-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270056, encodeId=2d0212e0056c3, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Fri May 18 04:42:00 CST 2018, time=2018-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542152, encodeId=ced7154215278, content=<a href='/topic/show?id=669d6185e3e' target=_blank style='color:#2F92EE;'>#柠檬酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61857, encryptionId=669d6185e3e, topicName=柠檬酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=725913361726, createdName=ms5236388012055669, createdTime=Fri May 18 04:42:00 CST 2018, time=2018-05-18, status=1, ipAttribution=)]

相关资讯

J CLIN INVEST :科学家发现新药可逆转糖尿病眼病!

对于数以百万计的美国人来说,他们的世界正在溶化成一个无法辨认的模糊视野。糖尿病性视网膜病是一种眼病,影响了3000万(与糖尿病斗争的三分之一人)美国人。随着患者的视力逐渐消失,它永远不会恢复,很少有治疗方法。

J Clin Endocrinol Metab:上海巴斯德所等揭示炎性因子IL-17A调控甲状腺相关眼病发生发展新机制

近期,美国内分泌学会主办的学术期刊Journal of Clinical Endocrinology and Metabolism 在线发表了中国科学院上海巴斯德研究所李斌课题组与中国科学院上海生命科学研究院/上海交通大学医学院健康科学研究所范先群课题组的合作研究成果,揭示了炎性因子IL-17A调控甲状腺相关眼病(Thyroid-associated ophthalmopathy,TAO)发生发展

游泳戴隐形眼镜致视力严重受损,夏季游泳如何防眼病

一男性青年去欢乐谷玩,游泳戴着隐形眼镜,眼睛不适后没有注意及时就医,直至回家后发现眼睛红得厉害,来就医时角膜已经发炎混浊,视力严重受损。每年夏季医院都会接诊不少游泳导致眼部疾病的病例。复旦大学附属眼耳鼻喉科医院眼科主治医师、哈佛大学医学院博士后洪佳旭医生近日就接诊了上述这例令其印象深刻的案例。夏季是各种病原微生物快速生长和传播的季节,是各种眼表疾病高发的季节,平均感染率是冬季的两倍,尤其是公共游泳

Immunity:眼睛内也存在益生菌?

你的眼睛里可能容不下一粒沙子,却容得下许多微生物。不仅如此,这些微生物还可以保护眼睛免受病原体感染。近日发表在《Immunity》杂志上的一篇论文首次证明了眼睛微生物组的存在。

国际盲人节:我国每分钟就有一人致盲

10月15日是第三十四个国际盲人节,而国人对致盲眼病了解的太少了,为您梳理一下吧!早在2006年,北京协和医院赵家良教授在东、中、西部各选三个省份,进行了五万多人群的样本调查,结果发现,50岁以上的盲人占到人口的1.93%,中重度视力损伤的人群占到5.3%左右,这就意味着我国盲人总数在300多万,这还不包括1700多万中重度视力损伤人群。由赵家良教授提供的最新独家数据是,中国每年新增盲人数量达45

《细胞》封面作者张康:AI诊断眼病是这样超越人类的

北京时间2月23日凌晨,张康团队及其合作者在顶级学术期刊《细胞》(Cell)发表封面文章“Identifying Medical Diagnoses and Treatable Diseases by Image-Based Deep Learning”。这项最新研究训练了一个基于“迁移学习”的全新AI诊断工具,可通过视网膜OCT(光学相干断层扫描)图像筛查致盲性视网膜疾病,并能在30秒内决定患者